Vir Biotechnology Inc is set to report fourth-quarter results today after the market close, with analysts expecting the clinical-stage biotech to post narrower losses as it advances its promising ...

Today, I explain why I've taken a position in VIR, including going over its pipeline, partners, and anticipated milestones. I then look at the company's valuation and cash position as well as Seeking ...

VIR took a big hit in July with the failure of the company's trial in influenza, but the stock has continued to slide since. A new BARDA contract to develop a COVID antibody and another drug against a ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it has entered into an exclusive worldwide license agreement with Sanofi for three clinical-stage masked ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it will be presenting new data from its ongoing Phase 2 SOLSTICE and MARCH trials evaluating the potential ...

– Virtual R&D Day webcast scheduled for today, Wednesday, April 27, at 12:00 pm ET / 9:00 am PT – SAN FRANCISCO, April 27, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today ...

BofA Securities has upgraded Vir Biotechnology (NASDAQ:VIR) to buy from neutral saying that the market is underestimating the company's phase 3 combo treatment for severe liver disease caused ...

Vir Biotechnology, Inc. (VIR) shares soared 6.9% in the last trading session to close at $6.05. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Vir Biotechnology, Inc. (NASDAQ:VIR) stands against the other ...

The AASLD late breaking presentation abstracts can be accessed under Events & Presentations in the Investors section of the Vir website here. Vir will host an investor conference call to discuss the ...